Chemotherapy of elderly patients with colorectal cancer;Idoskorú kolorektális daganatos betegek gyógyszeres kezelése

Magyar Onkologia

Volumn 53, Issue 2, 2009, Pages 97-105

  László, Landherr ^a   Tamás, Nagykálnai ^a  

^a Onkológiai Gondozó ^*  (Hungary)

Author keywords

Chemotherapy; Colorectal cancer; Elderly patients; Systemic therapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HUMAN; INJECTION SITE REACTION; LIFE EXPECTANCY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; AGE; COLORECTAL TUMOR; COOPERATION; DECISION MAKING; PATHOLOGY; PATIENT CARE; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMORBIDITY; COOPERATIVE BEHAVIOR; DECISION MAKING; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LIFE EXPECTANCY; ORGANOPLATINUM COMPOUNDS; PATIENT CARE TEAM;

EID: 69849089895     PISSN: 00250244     EISSN: None     Source Type: Journal    
DOI: 10.1556/MOnkol.53.2009.2.1     Document Type: Article

References (59)

1. Ananda S, Field KM, Kosmider S, et al. Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. J Clin Oncol 26:4516-4517, 2008
2. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000
3. Barni S, Cabbidu M, Petrelli F. Toxicity of targeted therapies in elderly patients. Expert Rev Anticancer Ther 8:1965-1976, 2008
4. Barrueco J, Marschall J, Michell E, et al. Safety and efficacy of the first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those ≤65. The BICC-C study. Proc ASCO 25(Suppl 18):182s, Abstr 4076, 2007
5. Bollina R, Beretta G, Toniolo D, et al. Capecitabine© and irinotecan (I) (CAPIRI) : A good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first-line chemotherapy (CT). Preliminary results of a phase II trial. Proc ASCO 22:1332, 2003
6. Bouchahda M, Maraculla T, Spano JP. Cetuximab and irinotecanbased chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer. Proc ASCO 25(Suppl 18):627s, Abstr 14528, 2007
7. Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91:1453-1458, 2004
8. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 104:282-289, 2005
9. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
10. Feliú J, Escudero P, Losa F, et al. A Phase II sudy of capecitabine (X) in elderly patients (p) as 1st line treatment for patients (pts) with advanced or metastatic colorectal cancer (MCRC). Proc ASCO 22:3567, 2004
11. Feliú J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as fi rst-line treatment of elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94:969-975, 2006
12. Feliú J, Salut A, Safont M, et al. First-line bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial. J Clin Oncol 26 (Suppl) : Abstr 15120, 2008
13. Field K, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: Results of a nationwide survey. J Oncol Pract 4:108-113, 2008
14. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 15:1330-1338, 2004
15. Folprecht G, Seymour MT, Saltz L, et al: Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2, 691 patients in randomized controlled trials. J Clin Oncol 26:1443-1451, 2008
16. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004
17. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006
18. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. The Oncologist 10 (Suppl 3):40-48, 2005
19. Gravalos C, Rivers F, Massuti B, et al. Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC) : preliminary results of TTD trial. J Clin Oncol 26 (Suppl) : Abstr 15027, 2008
20. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage ii and iii colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8670-8678, 2005
21. Ho C, O'Reilly S, Ng K, et al. Population-based analysis of patients with advanced colorectal cancer: The impact of age on treatment and outcomes. J Clin Oncol 23:274s, Abstr 3614, 2005
22. Hochster HS, Luo W, Popa EC, et al. Phase II study of uracil-tegafur with leucovorin in elderly (≥75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 25:5397-5402, 2007
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
24. Iwashyna TJ, Lamont EB. Eff ectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20:3992-3998, 2002
25. Jensen SA, Lønborg JT, Sorensen JB. Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experience. Acta Oncol 45:67-76, 2006
26. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentation. JAMA 294:2703-2711, 2005
27. Kabbinavar FF, Schultz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
28. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patients age and comorbidity? J Clin Oncol 26:2532-2537, 2008
29. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23:4553-4560, 2005
30. Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer: results from the BRiTE observational cohort study. J Clin Oncol 26 (Suppl) : Abstr 4026, 2008
31. Köhne C-H, Folprecht G, Goldberg RM, et al. Chemotherapy in elderly patients with colorectal cancer. Oncologist 13:390-402, 2008
32. Levi F, Zidani R, Focan C, et al. Age-independent benefit of chronotherapy with 5-fluorouracil, leucovorin, and oxaliplatin in patients with metastatic colorectal cancer within multicenter randomized Phase III trials. Proc ASCO 21:1431, 2002
33. Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patients: pharmacology and polypharmacy. Curr Treat Options Oncol 9:191-203, 2008
34. Lichtman SM, Eildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol 25:1832-1843, 2007
35. Mitry E, Tournigand C, André T, et al. Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer - a pooled analysis of 254 patients included in 2 randomized trials. Proc ASCO 22:3576, 2004
36. Muss HB, Biganzoli L, Sargent DJ, Aapro M. Adjuvant therapy in the elderly: Making the right decision. J Clin Oncol 25:1870-1875, 2007
37. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial difference in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-1202, 2002
38. Puthillath AA, Mashtare T, Wilding G, et al. A Phase II study of first-line biweekly regimen of capecitabine (CAP) and bevacizumab (BV) in elderly patients with metastatic colorectal cancer. Gastrointestinal Cancer Symposium, Orlando FL, USA, 25-27 January 2008, Abstr 511
39. Raman AK, Lombardo JC, Chandrasekhar R, et al. Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer. Proc ASCO 25 (18 Suppl) : Abstr 14546, 2007
40. Rosati G, Cordio S, Tucci A, et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 69:122-129, 2005
41. Rougier P, Mitry E, Cunningham D, et al. Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc ASCO 22:1072, 2003
42. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
43. Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol 25:1891-1897, 2007
44. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
45. Sargent J, Wieand HS, Benedetti J, et al. Disease-free survival vs overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12, 915 patients on 15 randomized trials. J Clin Oncol 22 (Suppl) :246a, Abstr 3502, 2004
46. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23:3545-3551, 2005
47. Saunders M, Iveson T. Management of advanced colorectal cancer: State of the art. Br J Cancer 95:131-138, 2006
48. Scappaticci FA, Skillings JR, Holden N, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239, 2007
49. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
50. Seymour MT, Maughan TS, Wasan HS, et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. Proc ASCO 25:9030, 2007
51. Skillings JR, Johnson DH, Miller F, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc ASCO 23:3019, 2005
52. Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan (CPT11) plus 5-flourouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 69:384-390, 2005
53. Sugrue MM, Kozloff H, Hainsworth J, et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: Results from the BRiTE registry. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 19-21 January 2007, Abstr 345
54. Sugrue MM, Yi J, Purdie DM, et al. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) : results from the BRiTE registry. Proc ASCO 25(18 Suppl):Abstr 4136, 2007
55. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349-357, 2002
56. Tabah-Fisch I, Maindrault-Goebel F, Benavides M, et al. Oxaliplatin/5FU/LV is feasible, safe, and active in elderly colorectal cancer (CRC) patients. Proc ASCO 21:56, 2002
57. Terret C, Zulian GB, Naiem A, et al. Multidisciplinary approach to the geriatric oncology patients. J Clin Oncol 25:1876-1881, 2007
58. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GRECOR study. J Clin Oncol 22:229-237, 2004
59. Twelves C, Butts CA, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large Phase II study. Clin Colorectal Cancer 5:101-107, 2005